Malvern (Global HQ)
PA, USA- HotSpot™ kinase profiling
- Biochemical and biophysical assays
- Cellular target engagement
- Recombinant protein production
A Partner for Every Stage and Milestone
For 25 years, drug developers have trusted Reaction Biology as a consultative CRO. You work directly with the scientists who design and run your experiments, gaining a partner invested in reaching your next milestone.
- Discovery
- Preclinical
- Clinical Support
About Reaction Biology
Reaction Biology is a consultative drug discovery and development CRO that elevates the standard for data quality and scientific partnership.
As a single partner supporting programs from discovery through preclinical and clinical development, our expertise spans multiple drug modalities, target classes, and therapeutic areas. Capabilities range from biochemical, cellular, and biophysical assays to in vitro safety testing, in vivo pharmacology and immuno-oncology studies, and GMP-compliant bioassays. Our expansive target portfolio includes the industry’s largest kinase assay library.
Headquartered in the United States, we operate four sites across North America and Europe, supporting a global customer base. With more than 25 years of scientific experience and a proven track record, our data has contributed to the advancement of hundreds of novel oncology programs through IND submission.
Quality systems are built for the audits your program will eventually require. Reaction Biology Europe operates under an ISO 9001:2015-certified quality management system for the development, production, and sale of recombinant protein products, biochemical, cellular, and immuno-oncology assay services, and in vivo testing services. BSL2-equipped labs enable in vivo efficacy studies across a broad range of therapeutic modalities: from small molecules, antibodies, and ADCs to oncolytic viruses and bacteria-based agents.
Our Platform
Target ID /
Validation
Target Assay
Development
Screening, Hit
ID and Validation
Hit to Lead
Lead
Optimization
Pre-clinical
Validation
Clinical
Development
Registration
Assay Development
Recombinant Proteins: >1,000 assay-ready proteins + custom substrates
Protein and Peptide Production
Biochemical Assays: Industry's largest kinase library, >2,000 targets, screening panels, custom assays
Biophysical Assays: SPR binding kinetics, ITC, DSF/thermal shift, MST
Cellular Biology: NanoBRET, target engagement, proliferation panels, IO functional assays
In Vivo: Xenograft, syngeneic, orthotopic, humanized, PK-PD
In Vitro Safety: Panels, hERG, ion channels, CYP/PDE
GMP Potency & Bioanalysis
Antibody / Biomarker Assays
GLP Tox / Safety
Global Footprint
- Founded in 2001 in Malvern, Pennsylvania, Reaction Biology has grown from a kinase screening specialist into a consultative drug discovery and development CRO serving the global pharmaceutical and biotech industry.
- Over 25 years, we have continuously expanded our assay portfolio, therapeutic coverage, and geographic footprint — now spanning four research locations across the US and Europe.
- Our global footprint has grown to include three other strategic research locations for regional accessibility.
Hershey
PA, USA- In vivo pharmacology: xenograft, syngeneic, and orthotopic models
- Integrated PK/PD
- Bioanalytical support
Freiburg
Germany- Biochemical screening
- Cellular assays
- In vivo efficacy
- Immuno-oncology models and flow cytometry
Heidelberg
Germany- GMP potency
- Functional bioassays
- GLP acute toxicology
- GCP-compliant studies
- IND/CTA-enabling analytical support
Why partner with us?
Trusted Partnership
Why researchers continuously rely on us to help achieve their milestones
Proven Track Record
Advance your program with confidence.
Our data has contributed to hundreds of oncology drug discovery programs submitted to IND.
Breadth of Experience
Partner with a team that’s delivered results at scale.
25 years of experience, 2,500+ clients, and 5,000+ projects each year.
Consultative Approach
Get more than data.
Our experienced scientists help you scope the right study, interpret results, and plan with confidence.
Aligned With Your Goals
Work with a team invested in your success.
We operate as an extension of your team, focused on helping you reach your next milestone.
Scientific Excellence
Why challenging programs come to us for high-quality data
Gold-Standard Methodologies
Build your program on proven science.
Stringently validated protocols, rigorous quality standards, and cutting-edge instrumentation across all four global sites.
Measurable Quality
Operations built for accountability.
Quality protocols backed by certified QMS (ISO 9001:2015) with on-time delivery and right-first-time metrics.
Deep Expertise
Leverage deep oncology knowledge.
Industry’s largest kinase library and specialized capabilities for the most complex drug discovery challenges.
Custom Development
Solve problems that don’t fit standard protocols.
Our scientists design custom experiments optimized around your specific compound, target, and scientific questions.
Client Experience
Why our partners continue to work with us
Proactive Communication
Stay informed with transparent updates.
Receive correspondence directly from the scientists running your experiments.
Reports On Schedule
Plan your next steps with confidence.
Proven on-time rating ensures your data arrives when promised, aligned to your deadlines.
Flexible Execution
Adapt with us when your program evolves.
Seamlessly adjust scope and timelines with accessible guidance from our team.
Agile Team
Ready when you are.
Responses to new inquiries within 24 hours and rapid quote delivery to expedite project start.
The CBC Network
Reaction Biology is one of a select group of institutions chosen to take part in the Chemical Biology Consortium (CBC), the drug discovery engine of the National Cancer Institute’s Experimental Therapeutics (NExT) Program.
NExT is an end-to-end discovery and development framework run by the NCI and the Frederick National Laboratory for Cancer Research. It advances investigator-led cancer programs from the bench toward the clinic, with a deliberate focus on the rare and underserved indications that the public and private sectors often leave behind.
As one of the few CROs in the consortium, Reaction Biology contributes the validated, fit-for-purpose assays and profiling that help NExT teams decide which compounds to advance.